{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:38:33Z","timestamp":1770068313178,"version":"3.49.0"},"reference-count":148,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacological management in the axial spondyloarthritis (axSpA) field has advanced in recent years. Accumulating evidence on long-term efficacy and safety of biological agents targeting TNFa and IL-17, as well as data on JAK inhibitors is now available. Rheumatologists have currently more options for treatment as compared with 20\u2009years ago, but choosing the best therapeutical approach for a single patient remains a challenge. Despite generalized treatment recommendations provided by international societies, patients present with a heterogeneity of symptoms and treatment responses. In the context of personalized medicine, understanding the disease phenotype in combination with extra-musculoskeletal manifestations is a core step for treatment decision making. Beyond disease-related aspects, comorbidities could also be particularly relevant in the selection of the most appropriate drug, given their different efficacy and safety profiles. AxSpA patient\u2019s fertility and pregnancy outcomes with regard to therapy also form a consideration, since symptom onset usually falls into the child-bearing age. This article will discuss the selective effect of the approved treatment modalities on the different axSpA manifestations and co-existing conditions.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaf513","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:05:21Z","timestamp":1758801921000},"source":"Crossref","is-referenced-by-count":0,"title":["Choosing treatment and targeted therapy in axial spondyloarthritis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-1106","authenticated-orcid":false,"given":"Kalliopi","family":"Klavdianou","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum , Herne,","place":["Germany"]},{"name":"Department of Rheumatology, \u2018Asklepieion\u2019 General Hospital , Voula, Athens,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum , Herne,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2026020205380523300_keaf513-B1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet (London, England)"},{"key":"2026020205380523300_keaf513-B2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis [Internet]"},{"key":"2026020205380523300_keaf513-B3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard-2023-225185","article-title":"Goodbye to the term \u201cankylosing spondylitis\u201d, hello \u201caxial spondyloarthritis\u201d: time to embrace the ASAS-defined nomenclature","volume":"83","author":"van der Heijde","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026020205380523300_keaf513-B5","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B7","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/ard.2011.150037","article-title":"A stratified model for health outcomes in ankylosing spondylitis","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/rheumatology\/keaa353","article-title":"Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort","volume":"60","author":"Hirano","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004756","article-title":"Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study","volume":"11","author":"Perez-Alamino","year":"2025","journal-title":"RMD open"},{"key":"2026020205380523300_keaf513-B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B11","first-page":"1015","author":"Siebert","year":"2019"},{"key":"2026020205380523300_keaf513-B12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/annrheumdis-2019-216516","article-title":"What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B16","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B17","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1093\/rheumatology\/keab887","article-title":"Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis","volume":"61","author":"De Craemer","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B18","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1093\/rheumatology\/keab873","article-title":"Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations","volume":"61","author":"Costantino","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B19","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane database Syst Rev"},{"key":"2026020205380523300_keaf513-B20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acr.22195","article-title":"Value of contrast-enhanced ultrasonography for the detection and quantification of enthesitis vascularization in patients with spondyloarthritis","volume":"66","author":"Mouterde","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205380523300_keaf513-B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/kes251","article-title":"Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)","volume":"52","author":"van der Heijde","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.160387","article-title":"Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab","volume":"44","author":"Mease","year":"2017","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B23","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3899\/jrheum.201111","article-title":"Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies","volume":"48","author":"Schett","year":"2021","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B25","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","article-title":"Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial","volume":"61","author":"Behrens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B26","first-page":"1004","author":"Deodhar","year":"2021"},{"key":"2026020205380523300_keaf513-B27","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2026020205380523300_keaf513-B28","first-page":"1515","author":"van der Heijde","year":"2022"},{"key":"2026020205380523300_keaf513-B29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2026020205380523300_keaf513-B30","doi-asserted-by":"crossref","first-page":"e002049","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"2026020205380523300_keaf513-B31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205380523300_keaf513-B32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B33","doi-asserted-by":"crossref","first-page":"1759720X20972610","DOI":"10.1177\/1759720X20972610","article-title":"The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study","volume":"12","author":"Redeker","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026020205380523300_keaf513-B34","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2026020205380523300_keaf513-B35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/rheumatology\/keae003","article-title":"Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis","volume":"64","author":"Kwon","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/art.42788","article-title":"Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: a systematic review and network meta-analysis","volume":"76","author":"Bechman","year":"2024","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026020205380523300_keaf513-B39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"2026020205380523300_keaf513-B40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B41","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"2026020205380523300_keaf513-B43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2026020205380523300_keaf513-B44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","article-title":"Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials","volume":"26","author":"Deodhar","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026020205380523300_keaf513-B46","doi-asserted-by":"crossref","first-page":"e005026","DOI":"10.1136\/rmdopen-2024-005026","article-title":"Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb\/III clinical studies","volume":"11","author":"Mease","year":"2025","journal-title":"RMD Open"},{"key":"2026020205380523300_keaf513-B47","doi-asserted-by":"crossref","first-page":"103533","DOI":"10.1016\/j.autrev.2024.103533","article-title":"The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus","volume":"23","author":"Macaluso","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026020205380523300_keaf513-B48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2026020205380523300_keaf513-B49","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2026020205380523300_keaf513-B50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.semarthrit.2018.10.019","article-title":"The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis","volume":"48","author":"Baraliakos","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3899\/jrheum.160003","article-title":"Serum C-reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab","volume":"43","author":"Braun","year":"2016","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B54","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis [Internet]"},{"key":"2026020205380523300_keaf513-B55","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/rheumatology\/keac104","article-title":"Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40744-024-00660-7","article-title":"Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: post hoc analysis from a large randomized clinical trial","volume":"11","author":"de Vlam","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026020205380523300_keaf513-B57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3899\/jrheum.2023-1198","article-title":"Efficacy and safety of tofacitinib in ankylosing spondylitis by baseline C-reactive protein level: post hoc analysis of phase II and phase III clinical trials","volume":"1","author":"Deodhar","year":"2024","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B59","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026020205380523300_keaf513-B60","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026020205380523300_keaf513-B61","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/acr2.11469","article-title":"Certolizumab pegol efficacy in patients with non-radiographic axial spondyloarthritis stratified by baseline MRI and C-reactive protein status: an analysis from the C-axSpAnd study","volume":"4","author":"Robinson","year":"2022","journal-title":"ACR open Rheumatol"},{"key":"2026020205380523300_keaf513-B62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-021-02613-9","article-title":"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT","volume":"23","author":"Braun","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026020205380523300_keaf513-B63","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","article-title":"Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B64","doi-asserted-by":"crossref","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","article-title":"Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Zhao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B65","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/acr.23468","article-title":"Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the assessment of spondyloarthritis international society comorbidities in spondyloarthritis study","volume":"70","author":"Nikiphorou","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205380523300_keaf513-B66","doi-asserted-by":"crossref","first-page":"151938","DOI":"10.1016\/j.semarthrit.2021.12.007","article-title":"Impact of the number of comorbidities on the outcome measures and on the retention rate of the first anti-TNF in patients with Ankylosing Spondylitis. Two-year follow-up in REGISPONSER-AS","volume":"52","author":"Puche-Larrubia","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B67","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","volume":"61","author":"Kerola","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B69","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2018-213089","article-title":"Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis","volume":"77","author":"Dubreuil","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2014-206147","article-title":"Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study","volume":"75","author":"Essers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B71","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B72","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study","volume":"163","author":"Haroon","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026020205380523300_keaf513-B74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/rheumatology\/kead684","article-title":"Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis","volume":"64","author":"Kim","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B75","first-page":"2440","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab","volume":"33","author":"Spanakis","year":"2006","journal-title":"J Rheumatol"},{"key":"2026020205380523300_keaf513-B76","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","volume":"74","author":"van Sijl","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B78","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/rheumatology\/kead072","article-title":"Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study","volume":"62","author":"Fakih","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B79","doi-asserted-by":"crossref","first-page":"152482","DOI":"10.1016\/j.semarthrit.2024.152482","article-title":"The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis","volume":"68","author":"Liew","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","article-title":"Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications","volume":"9","author":"Merola","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026020205380523300_keaf513-B81","doi-asserted-by":"crossref","first-page":"679009","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in cantabria and ASTURias study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front Med"},{"key":"2026020205380523300_keaf513-B82","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B83","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B84","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2026020205380523300_keaf513-B85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, NJ"},{"key":"2026020205380523300_keaf513-B86","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-025-01578-x","article-title":"Major adverse cardiovascular events related to JAK inhibitors: a disproportionality analysis using the WHO global individual case safety database","volume":"48","author":"Di Napoli","year":"2025","journal-title":"Drug Saf"},{"key":"2026020205380523300_keaf513-B87","first-page":"1194","author":"Aymon","year":"2025"},{"key":"2026020205380523300_keaf513-B88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clinthera.2025.01.005","article-title":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis","volume":"47","author":"Zhao","year":"2025","journal-title":"Clin Ther"},{"key":"2026020205380523300_keaf513-B89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semarthrit.2017.12.001","article-title":"Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis","volume":"48","author":"Ram\u00edrez","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B90","doi-asserted-by":"crossref","first-page":"569449","DOI":"10.3389\/fmed.2020.569449","article-title":"A contemporary view of the diagnosis of osteoporosis in patients with axial spondyloarthritis","volume":"7","author":"Lim","year":"2020","journal-title":"Front Med"},{"key":"2026020205380523300_keaf513-B91","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00296-012-2632-9","article-title":"Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis","volume":"33","author":"Ulu","year":"2013","journal-title":"Rheumatol Int"},{"key":"2026020205380523300_keaf513-B92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/kev332","article-title":"Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort","volume":"55","author":"Briot","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B93","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/jbmr.2217","article-title":"Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study","volume":"29","author":"Mu\u00f1oz-Ortego","year":"2014","journal-title":"J bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"2026020205380523300_keaf513-B94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00198-014-2939-3","article-title":"Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study","volume":"26","author":"Prieto-Alhambra","year":"2015","journal-title":"Osteoporos Int"},{"key":"2026020205380523300_keaf513-B95","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semarthrit.2014.05.008","article-title":"Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"44","author":"Haroon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B96","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.201141871","article-title":"Anti IL-17A therapy inhibits bone loss in TNF-\u03b1-mediated murine arthritis by modulation of the T-cell balance","volume":"42","author":"Zwerina","year":"2012","journal-title":"Eur J Immunol"},{"key":"2026020205380523300_keaf513-B97","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s12891-021-04930-1","article-title":"Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1","volume":"22","author":"Braun","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"2026020205380523300_keaf513-B98","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00198-017-4189-7","article-title":"Inflammatory diseases and bone fragility","volume":"28","author":"Briot","year":"2017","journal-title":"Osteoporos Int"},{"key":"2026020205380523300_keaf513-B99","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12016-017-8623-6","article-title":"The comparative safety of TNF inhibitors in ankylosing spondylitis-a meta-analysis update of 14 randomized controlled trials","volume":"54","author":"Hou","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026020205380523300_keaf513-B101","author":"Sebbag","year":"2024"},{"key":"2026020205380523300_keaf513-B102","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026020205380523300_keaf513-B103","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/jcm13206216","article-title":"Secukinumab may be an effective treatment option for axial spondyloarthritis and psoriatic arthritis patients with a history of malignancy: multicenter real-life experience from Turkey","volume":"13","author":"Ocak","year":"2024","journal-title":"J Clin Med"},{"key":"2026020205380523300_keaf513-B104","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00296-024-05571-y","article-title":"Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease","volume":"44","author":"Farina","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026020205380523300_keaf513-B105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/RHU.0000000000002175","article-title":"Risk of malignancy related to ixekizumab in patients with psoriatic arthritis or axial spondyloarthropathy: systematic review and meta-analysis","volume":"31","author":"Maneiro","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"2026020205380523300_keaf513-B106","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/RHU.0000000000002188","article-title":"Risk of cancers according to the use of biological agents in patients with radiographic axial spondyloarthritis: a nationwide population-based cohort study","volume":"31","author":"Kwon","year":"2025","journal-title":"J Clin Rheumatol Pract"},{"key":"2026020205380523300_keaf513-B107","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B109","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B110","doi-asserted-by":"crossref","first-page":"105673","DOI":"10.1016\/j.jbspin.2023.105673","article-title":"Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials","volume":"91","author":"S\u00e9auve","year":"2024","journal-title":"Jt bone spine"},{"key":"2026020205380523300_keaf513-B111","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","article-title":"Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"69","author":"Fouque-Aubert","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/keu255","article-title":"Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort","volume":"54","author":"Wallis","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B113","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/03009742.2018.1470253","article-title":"Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis","volume":"48","author":"Moura","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2026020205380523300_keaf513-B114","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/14397595.2021.1878985","article-title":"The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors","volume":"31","author":"Koo","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026020205380523300_keaf513-B115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2013.834961","article-title":"Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis","volume":"43","author":"van der Heijde","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2026020205380523300_keaf513-B116","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026020205380523300_keaf513-B117","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B118","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B119","first-page":"664","author":"Nash","year":"2025"},{"key":"2026020205380523300_keaf513-B120","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/rheumatology\/keab544","article-title":"Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study","volume":"61","author":"Boel","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B121","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/acr.20510","article-title":"Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies","volume":"63","author":"Micu","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205380523300_keaf513-B122","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B123","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.fertnstert.2013.10.048","article-title":"Influence of tumor necrosis factor \u03b1 inhibitors on testicular function and semen in spondyloarthritis patients","volume":"101","author":"Ramonda","year":"2014","journal-title":"Fertil Steril"},{"key":"2026020205380523300_keaf513-B124","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020205380523300_keaf513-B125","first-page":"910","author":"R\u00fcegg","year":"2025"},{"key":"2026020205380523300_keaf513-B126","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/art.1780250204","article-title":"Ankylosing spondylitis and motherhood","volume":"25","author":"Ostensen","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B127","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.1780260915","article-title":"A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis","volume":"26","author":"Ostensen","year":"1983","journal-title":"Arthritis Rheum"},{"key":"2026020205380523300_keaf513-B128","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002146","article-title":"Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data","volume":"8","author":"Redeker","year":"2022","journal-title":"RMD open"},{"key":"2026020205380523300_keaf513-B129","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/keab589","article-title":"Fertility and pregnancy outcomes in women with spondyloarthritis: a systematic review and meta-analysis","volume":"61","author":"Hamroun","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B130","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/ard-2022-222641","article-title":"Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)","volume":"81","author":"Meissner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B131","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2665-9913(23)00001-2","article-title":"Temporal trends in adverse pregnancy outcomes in axial spondyloarthritis in Sweden: a cohort study","volume":"5","author":"Morin","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026020205380523300_keaf513-B132","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1093\/rheumatology\/keac552","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice","volume":"62","author":"Schreiber","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205380523300_keaf513-B133","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026020205380523300_keaf513-B134","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026020205380523300_keaf513-B135","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the american college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2026020205380523300_keaf513-B136","first-page":"3242","author":"Zhao","year":"2025"},{"key":"2026020205380523300_keaf513-B137","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2026020205380523300_keaf513-B138","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B139","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B140","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B141","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B142","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B143","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2026020205380523300_keaf513-B144","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00393-018-0446-1","article-title":"[Becoming older with axial spondyloarthritis]","volume":"77","author":"Kiltz","year":"2018","journal-title":"Z Rheumatol"},{"key":"2026020205380523300_keaf513-B145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/annrheumdis-2016-209233","article-title":"Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative","volume":"75","author":"Baillet","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026020205380523300_keaf513-B146","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/rheumatology\/kez125","article-title":"Using combinations of biomarkers to understand inflammation and bone formation in axial spondyloarthritis\u2014is anything better than CRP?","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026020205380523300_keaf513-B147","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD open"},{"key":"2026020205380523300_keaf513-B148","first-page":"927","author":"Winthrop","year":"2025"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf513\/64414878\/keaf513.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf513\/64414878\/keaf513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf513\/64414878\/keaf513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:30Z","timestamp":1770028710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf513\/8266350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf513","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,26]]},"article-number":"keaf513"}}